AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2462651 — intervention group
Group type: EXPERIMENTAL
Intervention: Estracyt (E) + Peplomycin (P) + Doxorubicin (Do) in Group 1
Number of subjects: 2
Study 2462651 — intervention group
Group type: EXPERIMENTAL
Intervention: E + P in Group 2
Number of subjects: 2
Study 2462651 — intervention group
Group type: COMPARATOR
Intervention: Various treatment subgroups
Number of subjects: 2
Study 2462651 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP-related response in Group 2
Number of subjects: 2
Study 31869494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation tube (VT) surgery
Number of subjects: 327
Study 31869494 — intervention group
Group type: EXPERIMENTAL
Intervention: VT surgery between 5 weeks and 6 months
Number of subjects: 327
Study 31869494 — intervention group
Group type: EXPERIMENTAL
Intervention: VT surgery between 6 and 12 months
Number of subjects: 327
Study 29038285 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction and aerobic exercise
Number of subjects: 111
Study 29038285 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction alone
Number of subjects: 111
Study 29038285 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise alone
Number of subjects: 111
Study 29038285 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (caloric restriction and aerobic exercise)
Number of subjects: 111
Study 29038285 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 111
Study 28843009 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional deep brain stimulation (DBS)
Number of subjects: 10
Study 28843009 — intervention group
Group type: COMPARATOR
Intervention: Circular deep brain stimulation (DBS)
Number of subjects: 10
Study 25377507 — intervention group
Group type: EXPERIMENTAL
Intervention: ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin)
Number of subjects: 140
Study 25377507 — intervention group
Group type: COMPARATOR
Intervention: pemetrexed and carboplatin (or cisplatin)
Number of subjects: 140
Study 21812822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Agility Exercise (IAE)
Number of subjects: 10
Study 21812822 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 10
Study 21812822 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study 21600163 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 40
Study 21600163 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 40
Study 21600163 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Remifentanil and Sufentanil
Number of subjects: 40
Study 18496020 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) course, 8 weeks duration, 15 participants
Number of subjects: 22
Study 18496020 — intervention group
Group type: COMPARATOR
Intervention: Untreated comparison group, 7 participants
Number of subjects: 22
Study 17142411 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular external fixation
Number of subjects: 82
Study 17142411 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation
Number of subjects: 82
Study 14520769 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-K (12.5 mg)
Number of subjects: 0
Study 14520769 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (500 mg)
Number of subjects: 0
Study 14520769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10716135 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg once daily
Number of subjects: 142
Study 10716135 — intervention group
Group type: COMPARATOR
Intervention: enalapril 20 mg once daily
Number of subjects: 142
Study 9178399 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms bid)
Number of subjects: 208
Study 9178399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 9178399 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms bid) and Placebo
Number of subjects: 208
Study 1283198 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 8 ml bupivacaine 0.5% + 5 ml lignocaine 2%
Number of subjects: 20
Study 1283198 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 20
Study 3087550 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous estradiol implants combined with cyclical oral norethisterone
Number of subjects: 68
Study 3087550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 29802443 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose X-82 (200 mg)
Number of subjects: 14
Study 29802443 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose X-82 (400 mg)
Number of subjects: 14
Study 29802443 — intervention group
Group type: COMPARATOR
Intervention: X-82 alone (cycle 1)
Number of subjects: 14
Study 29802443 — intervention group
Group type: EXPERIMENTAL
Intervention: X-82 plus docetaxel (cycle 2)
Number of subjects: 14
Study 26385456 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal yoga intervention
Number of subjects: 0
Study 26385456 — intervention group
Group type: COMPARATOR
Intervention: Perinatal-focused health education (Control)
Number of subjects: 0
Study 24524389 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Group A)
Number of subjects: 310
Study 24524389 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics (Group B)
Number of subjects: 310
Study 24524389 — intervention group
Group type: COMPARATOR
Intervention: Neither probiotics nor oral antibiotics (Group C)
Number of subjects: 310
Study 22875686 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory research elective class
Number of subjects: 401
Study 22875686 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 401
Study 20725123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic exposure (IHE)
Number of subjects: 9
Study 18848381 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20mg daily for 90 days)
Number of subjects: 89
Study 18848381 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (10 sessions)
Number of subjects: 89
Study 18848381 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study 15679557 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 1034
Study 15679557 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 1034
Study 15679557 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 1034
Study 14501863 — intervention group
Group type: EXPERIMENTAL
Intervention: Right liver graft without MHV trunk or MHV reconstruction (n=17)
Number of subjects: 56
Study 14501863 — intervention group
Group type: EXPERIMENTAL
Intervention: Right liver graft without MHV trunk, but with MHV reconstruction (n=27)
Number of subjects: 56
Study 14501863 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended right liver graft (n=12)
Number of subjects: 56
Study 10596917 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) 800 mg/m2 every 21 days, IL-2 9 MIU subcutaneously days 1-5 and 8-12, interferon 3 MU subcutaneously three times a week, tamoxifen 20 mg orally throughout
Number of subjects: 92
Study 10596917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m2 days 1-3, DTIC 250 mg/m2 days 1-3, vindesine 2.5 mg/m2 day 1 every 28 days, interferon 3 MU subcutaneously three times a week, tamoxifen 20 mg orally throughout
Number of subjects: 92
Study 10596917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, DTIC, vindesine (CVD) plus IL-2 6 MIU days 1-5 and 8-12 every 28 days, interferon 3 MU subcutaneously three times a week, tamoxifen 20 mg orally throughout
Number of subjects: 92
Study 10596917 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms (A, B, C)
Number of subjects: 92
Study 8992424 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (100 mg/m2/1h) administered immediately before and at the end (24th h) of methotrexate treatment
Number of subjects: 2
Study 8992424 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (100 mg/m2/1h) administered at 24 h and at 48 h after starting methotrexate infusion
Number of subjects: 2
Study 1714948 — intervention group
Group type: COMPARATOR
Intervention: Surveillance only
Number of subjects: 150
Study 1714948 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy after orchiectomy
Number of subjects: 150
Study 7105823 — intervention group
Group type: EXPERIMENTAL
Intervention: Film-coated indoramin (50 mg tablets)
Number of subjects: 7
Study 7105823 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated indoramin (50 mg tablets)
Number of subjects: 7
Study 7105823 — intervention group
Group type: EXPERIMENTAL
Intervention: Film-coated indoramin after a standard meal
Number of subjects: 7
Study 7105823 — intervention group
Group type: EXPERIMENTAL
Intervention: Film-coated indoramin (2 tablets)
Number of subjects: 7
Study 31491757 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural and general anesthesia, followed by epidural analgesia for 48 hours after surgery
Number of subjects: 48
Study 31491757 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia, followed by traditional opioid pain management after surgery
Number of subjects: 48
Study 26082384 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminectomy followed by fusion
Number of subjects: 18
Study 26082384 — intervention group
Group type: COMPARATOR
Intervention: Laminectomy without fusion
Number of subjects: 18
Study 26265232 — intervention group
Group type: EXPERIMENTAL
Intervention: PH‐797804 30 mg (oral)
Number of subjects: 0
Study 26265232 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐03715455 20 mg (inhaled)
Number of subjects: 0
Study 26265232 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 μg (inhaled)
Number of subjects: 0
Study 26265232 — intervention group
Group type: EXPERIMENTAL
Intervention: PH‐797804
Number of subjects: 0
Study 26265232 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐03715455
Number of subjects: 0
Study 26265232 — intervention group
Group type: EXPERIMENTAL
Intervention: PH‐797804 and PF‐03715455
Number of subjects: 0
Study 26265232 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 0
Study 24603110 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilation by one-stage Amplatz (group II)
Number of subjects: 62
Study 24603110 — intervention group
Group type: COMPARATOR
Intervention: Dilation by serial metallic dilators (group I)
Number of subjects: 62
Study 24603110 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 22081122 — intervention group
Group type: COMPARATOR
Intervention: Traditional logopedic dysphagia treatment
Number of subjects: 88
Study 22081122 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional logopedic dysphagia treatment combined with NMES at sensor or motor level stimulation
Number of subjects: 88
Study 20815879 — intervention group
Group type: EXPERIMENTAL
Intervention: A-L dispersible tablet (cherry flavour)
Number of subjects: 48
Study 20815879 — intervention group
Group type: COMPARATOR
Intervention: A-L dispersible tablet (80 mg artemether + 480 mg lumefantrine)
Number of subjects: 48
Study 20815879 — intervention group
Group type: COMPARATOR
Intervention: A-L dispersible tablet
Number of subjects: 48
Study 17132823 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (2 mg daily)
Number of subjects: 9
Study 17132823 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (2 mg daily) + Acipimox (250 mg x 3 daily)
Number of subjects: 9
Study 17132823 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Placebo
Number of subjects: 9
Study 15876939 — intervention group
Group type: EXPERIMENTAL
Intervention: PnCV
Number of subjects: 0
Study 15876939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12059913 — intervention group
Group type: EXPERIMENTAL
Intervention: AH26
Number of subjects: 80
Study 12059913 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 80
Study 12059913 — intervention group
Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 80
Study 12059913 — intervention group
Group type: COMPARATOR
Intervention: Positive Control
Number of subjects: 80
Study 9536401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract/carboxymethyl-beta-1,3-glucan formulation applied 2X a day for 2 weeks
Number of subjects: 22
Study 9536401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7664371 — intervention group
Group type: EXPERIMENTAL
Intervention: One channel sputum sucking for 15 sec (Experimental Group A)
Number of subjects: 90
Study 7664371 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplied double channel sucking for 15 sec (Experimental Group B)
Number of subjects: 90
Study 7664371 — intervention group
Group type: COMPARATOR
Intervention: Channel sputum sucker under mechanical respiratory support (Contrast Group)
Number of subjects: 90
Study 2545773 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dextroamphetamine 20 mg
Number of subjects: 24
Study 2545773 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior treatment with pimozide
Number of subjects: 24
Study 2545773 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine
Number of subjects: 24
Study 2545773 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 24
Study 352197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloprednol
Number of subjects: 40
Study 352197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30747030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nostalgia condition
Number of subjects: 60
Study 30747030 — intervention group
Group type: COMPARATOR
Intervention: Ordinary condition (Control)
Number of subjects: 60
Study 27918172 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridges to High School intervention
Number of subjects: 516
Study 27918172 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 516
Study 25724103 — intervention group
Group type: EXPERIMENTAL
Intervention: Versajet™ hydrosurgery
Number of subjects: 61
Study 25724103 — intervention group
Group type: COMPARATOR
Intervention: Conventional debridement
Number of subjects: 61
Study 24342196 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron protein succinylate (IPS) oral solution
Number of subjects: 60
Study 24342196 — intervention group
Group type: COMPARATOR
Intervention: Polysaccharide iron complex (PIC)
Number of subjects: 60
Study 21679323 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided skiing for 12 weeks (IG)
Number of subjects: 42
Study 21679323 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 42
Study 19494809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-treated patients who were UGT1A9 -275T>A and/or -2152C>T carriers
Number of subjects: 338
Study 19494809 — intervention group
Group type: EXPERIMENTAL
Intervention: UGT1A9*3 carriers treated with tacrolimus
Number of subjects: 338
Study 19494809 — intervention group
Group type: EXPERIMENTAL
Intervention: UGT1A9*3 carriers treated with cyclosporine
Number of subjects: 338
Study 19494809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine-treated UGT1A8*2/*2 (518GG) patients
Number of subjects: 338
Study 19494809 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose MMF-treated patients receiving tacrolimus with UGT1A9 -275T>A and/or -2152C>T polymorphism
Number of subjects: 338
Study 16461866 — intervention group
Group type: EXPERIMENTAL
Intervention: CM and 300 mg/d of bupropion hydrochloride (CMB)
Number of subjects: 106
Study 16461866 — intervention group
Group type: EXPERIMENTAL
Intervention: CM and placebo (CMP)
Number of subjects: 106
Study 16461866 — intervention group
Group type: COMPARATOR
Intervention: voucher control and bupropion (VCB)
Number of subjects: 106
Study 16461866 — intervention group
Group type: COMPARATOR
Intervention: voucher control and placebo (VCP)
Number of subjects: 106
Study 15104569 — intervention group
Group type: COMPARATOR
Intervention: 75 IU rLH supplementation (group A)
Number of subjects: 46
Study 15104569 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU rLH supplementation (group B)
Number of subjects: 46
Study 15104569 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) with rFSH monotherapy
Number of subjects: 46
Study 15354458 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.42% fluoride gel (8 applications at 3-month intervals)
Number of subjects: 213
Study 15354458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride gel)
Number of subjects: 213
Study 9003817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 208
Study 9003817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 208
Study 8515294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 53
Study 8515294 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin plus amoxicillin
Number of subjects: 53
Study 3556337 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg orally
Number of subjects: 2
Study 28502270 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecure attachment (fearful-avoidant, dismissing, preoccupied)
Number of subjects: 162
Study 28502270 — intervention group
Group type: EXPERIMENTAL
Intervention: Fearful-avoidant attachment style
Number of subjects: 162
Study 28502270 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoccupied attachment style
Number of subjects: 162
Study 28502270 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecure attachment overall
Number of subjects: 162
Study 28502270 — intervention group
Group type: EXPERIMENTAL
Intervention: Dismissing attachment style
Number of subjects: 162
Study 26796355 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control >_75% of visits
Number of subjects: 6287
Study 26796355 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure control < 25% of visits
Number of subjects: 6287
Study 24599922 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics plus MTX
Number of subjects: 0
Study 24599922 — intervention group
Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 0
Study 23019142 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining a negative encounter followed by a positive encounter
Number of subjects: 0
Study 23019142 — intervention group
Group type: COMPARATOR
Intervention: Purely positive interventions
Number of subjects: 0
Study 23019142 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-valence imagery task
Number of subjects: 0
Study 19342020 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG supplementation (250 microg on day of P initiation, day of embryo transfer, and 6 days later)
Number of subjects: 165
Study 19342020 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard protocol for endometrial preparation)
Number of subjects: 165
Study 19342020 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG supplementation
Number of subjects: 165
Study 19342020 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 165
Study 18581464 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (group A)
Number of subjects: 50
Study 18581464 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol (group B)
Number of subjects: 50
Study 18581464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril added to partial responders
Number of subjects: 50
Study 16634036 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan/Quinidine (DM/Q)
Number of subjects: 150
Study 16634036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 14606933 — intervention group
Group type: COMPARATOR
Intervention: Pimecrolimus (5-60mg single dose)
Number of subjects: 0
Study 14606933 — intervention group
Group type: COMPARATOR
Intervention: Pimecrolimus (5-30mg multiple doses)
Number of subjects: 0
Study 11049696 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 24
Study 11049696 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal sodium diet)
Number of subjects: 24
Study 8773820 — intervention group
Group type: EXPERIMENTAL
Intervention: Aftercare worker service
Number of subjects: 32
Study 1475622 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated piroxicam tablets (20 mg once daily for 2 weeks)
Number of subjects: 16
Study 1475622 — intervention group
Group type: COMPARATOR
Intervention: Plain piroxicam tablets (20 mg once daily for 2 weeks)
Number of subjects: 16
Study 6383591 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunotherapy (intradermaIly with a Heaf gun and orally for 2 years)
Number of subjects: 199
Study 6383591 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up (Control)
Number of subjects: 199
Study 31717971 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Gaming (AG)
Number of subjects: 9
Study 31717971 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Gaming with wrist‐worn weights (AGW)
Number of subjects: 9
Study 31717971 — intervention group
Group type: COMPARATOR
Intervention: Walking at 6 km/h (W6)
Number of subjects: 9
Study 29941516 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 60
Study 29941516 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 25953451 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 132
Study 25953451 — intervention group
Group type: COMPARATOR
Intervention: Average Danish Diet (ADD)
Number of subjects: 132
Study 24565019 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Engagement (CE) activities
Number of subjects: 200
Study 22887155 — intervention group
Group type: EXPERIMENTAL
Intervention: dealcoholized red wine (RWD) (272mL/day, polyphenol control)
Number of subjects: 61
Study 22887155 — intervention group
Group type: EXPERIMENTAL
Intervention: alcoholized red wine (RWA) (272mL/day)
Number of subjects: 61
Study 22887155 — intervention group
Group type: COMPARATOR
Intervention: gin (GIN) (100mL/day, alcohol control)
Number of subjects: 61
Study 20054045 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment and chlorhexidine soap
Number of subjects: 917